James Harris
James Harris has extensive experience within biotech, pharmaceuticals and medical devices with small start-ups, mid-sized and large firms. Mr. Harris is CEO of Healthcare Economics LLC and co-founder of AS Biotech AG. Prior to this he served as Vice President at Dragon Pharmaceuticals, Inc. where he was instrumental in the launch and successful market penetration of rh-Erythropoietin (“EPO") in non patented markets and is very well experienced in in-out licensing and business development internationally. Mr. Harris is a participating board member of pharmaceutical companies and has participated extensively as a featured speaker at medical meetings as well as authoring “GCSF and Bioequivalence: “The Emergence of Healthcare Economics” WILEY-VCH, Weinheim, Germany and “Marketing and Globalizing Biosimilars” Journal of Generic Medicines, London, UK. http://www.healthcare-economics-llc.com
More content by James Harris
Biosimilars Landscape and FDA Regulatory Expectations
March 21 by James HarrisThe Congressional Budget Office (CBO) has estimated that the United States could save $25 billion from the use of biosimilars over 10 years. In a general sense the term biosimilars refers to fo...
Patient Empowerment and Compliance:The Role of Direct to Consumer (DTC) Advertising
May 26 by James HarrisIt is a given fact that more households are wired to the internet and individuals are introduced to an onslaught of information for various venues. The internet is a tool that allows individua...
